Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate
NDC 31722-736, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate, tablet, film coated, from Camber Pharmaceuticals, Inc..
- Product NDC
- 31722-736
- Status
- Listed
- Labeler
- Camber Pharmaceuticals, Inc.
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application
- ANDA203053
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/31722-736 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- EFAVIRENZ600 mg/1
- EMTRICITABINE200 mg/1
- TENOFOVIR DISOPROXIL FUMARATE300 mg/1
Pharmacologic classes
Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 2C19 Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inducers [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; Non-Nucleoside Analog [EXT]; Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleoside Reverse Transcriptase Inhibitors [MoA]; Nucleosides [CS]; Nucleosides [CS]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 31722-736-30 | 31722073630 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-736-30) |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/5f261872-d705-4549-a43d-2ad6b0164dc3NADAC price for package 31722073630
GET /v1/drugs/nadac/31722073630
Use it
Look up 31722-736 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/31722-736 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 31722-736. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.